 | DANIEL J SARGENTShow email addressAlliance Statistics and Data Center, Mayo Clinic, Rochester, MN. | Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA. | Formerly with Alliance Statistics ... |
Is this your profile? Claim your profile Copy URL Embed Link to your profile |
DANIEL J SARGENT:Expert Impact
Concepts for whichDANIEL J SARGENThas direct influence:Colon cancer,Colorectal cancer,Metastatic colorectal cancer,Phase iii,Adjuvant chemotherapy,Adjuvant therapy,Stage iii.
DANIEL J SARGENT:KOL impact
Concepts related to the work of other authors for whichfor which DANIEL J SARGENT has influence:Colorectal cancer,Adjuvant chemotherapy,Microsatellite instability,Elderly patients,Laparoscopic surgery,Cell lung,Liver metastases.
KOL Resume for DANIEL J SARGENT
| Year | |
|---|---|
| 2020 | Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN. |
| 2019 | Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA. Formerly with Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN. |
| 2018 | Department of Health Science Research, Mayo Clinic, Rochester, USA Alliance Statistics and Data Center, Mayo Clinic, Rochester, Minnesota |
| 2017 | Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, USA Columbia University, New York; Roswell Park Cancer Institute, Buffalo, NY; University of Texas MD Anderson Cancer Center, Houston; Castle Biosciences, Friendswood, TX; University of Florida Medical Center, Gainesville, FL; University of California Los Angeles Medical Center, Los Angeles; Biocept, San Diego, CA; University of Nebraska Medical Center, Omaha, NE; University of North Carolina School of Medicine, Chapel Hill, NC; University of Colorado Denver School of Medicine, Denver, CO; Mayo Clinic, Scottsdale, AZ; Mayo Clinic, Rochester, MN; Case Western Reserve University, Cleveland, OH; American Society for Clinical Pathology, Washington, DC; College of American Pathologists, Northfield, IL; American Society of Clinical Oncology, Alexandria, VA; and Association for Molecular Pathology, Bethesda, MD. Alliance for Clinical Trials in Oncology Statistics and Data Center, Mayo Clinic, Rochester, Minnesota Department of Health Sciences Research, Mayo Clinic, Rochester, MN |
| 2016 | Deceased. Mayo Medical Center, Rochester, MN, USA Alliance Statistics and Data Center |
| 2015 | Ming-Wen An, Vassar College, Poughkeepsie, NY; Yu Han, Novartis Pharmaceuticals, East Hanover NJ; Jeffrey Meyers, Daniel J. Sargent, and Sumithra J. Mandrekar, Mayo Clinic, Rochester, MN; and Jan Bogaerts, European Organisation for Research and Treatment of Cancer, Brussels, Belgium. Department of Health Science Research, Mayo Clinic, Rochester, Minnesota. Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN 55905, USA. Lindsay A. Renfro and Daniel J. Sargent, Mayo Clinic, Rochester, MN; Fotios Loupakis and Alfredo Falcone, Azienda Ospedaliero-Universitaria Pisana and Università di Pisa, Pisa, Italy; Richard Adams, Cardiff University, Cardiff; Matthew T. Seymour, St James's Hospital and University of Leeds, Leeds, United Kingdom; Volker Heinemann, University of Munich, Munich; Hans-Joachim Schmoll, University Clinic Halle (Saale), Halle; Rainer Porschen, Klinikum Bremen-Ost Klinik für Innere Medizin, Bremen; Carsten Bokemeyer, University Hospital Cancer Center, University Hospital, Hamburg-Eppendorf, Germany; Jean-Yves Douillard, Institut de Cancerologie, Centre René Gauducheau, Nantes; Christophe Tournigand, University of Paris Est Creteil, Henri-Mondor Hospital, Créteil; Benoist Chibaudel and Aimery de Gramont, Franco-British Institute, Levallois-Perret, France; Herbert Hurwitz, Duke University Medical Center, Durham, NC; Charles S. Fuchs, Dana-Farber Cancer Institute Boston, MA; Eduardo Diaz-Rubio, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Madrid, Spain; Niall C. Tebbutt, Austin Health, Heidelberg, Victoria, Australia; Cornelis J.A. Punt, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands; J. Randolph Hecht, David Geffen School of Medicine at the University of California at Los Angeles; Heinz-Josef Lenz, University of Southern California/Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA; Eric Van Cutsem, University Hospital Leuven, Leuven, Belgium; Richard M. Goldberg, Ohio State University, Columbus, OH; and Leonard B. Saltz, Memorial Sloan-Kettering Cancer Center, New York, NY. Mayo Clinic Cancer Center. |
| 2014 | Authors' Affiliations: Alliance Statistics and Data Center, Mayo Clinic, Rochester, Minnesota; Lehigh Valley Hospital, Allentown, Pennsylvania; and Ohio State University, Columbus, Ohio Department of Health Science Research, Mayo Clinic, 200 First Street SW, 5590, Rochester, MN, USA Division of Biomedical Statistics and Informatics, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, United States Biostatistics and Medical Oncology, Mayo Clinic, Rochester, Minnesota. |
| 2013 | Mayo Clinic, Rochester, MN Hôpital Saint Antoine, Paris, France Mayo Clinic, Rochester, MN |
| 2012 | Affiliations of authors: Division of Hematology and Oncology, Department of Medicine, University of Virginia, Charlottesville, VA (HKS); Department of Health Policy and Management (WRC), Department of Epidemiology (TS), and Department of Biostatistics (JPF), Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC; Division of Gastroenterology and Hepatology, Department of Medicine, University of North Carolina, Chapel Hill, NC (CFM); Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN (DJS); Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA (JAM, JW, DS); RAND Corporation, Santa Monica, CA (KLK); Division of General Internal Medicine and Health Services Research, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA (KLK); New York State Cancer Registry, New York State Department of Health, Albany, NY (MJS); Department of Information Sciences, City of Hope Cancer Center, Duarte, CA (JN); Data Coordinating Center for the National Comprehensive Cancer Center, Duarte, CA (JN) Mayo Clinic Division of Biomedical Statistics and Informatics Rochester MN 55905 U.S.A |
| Concept | World rank |
|---|---|
| phase iii surveys | #1 |
| parameters mcmo | #1 |
| obese patients dmmr | #1 |
| component endpoint data | #1 |
| rates surgical wounds | #1 |
| arcad clinical | #1 |
| additional meta analysis | #1 |
| wine outcomes | #1 |
| icer dly | #1 |
| biologically optimal dose | #1 |
| isolated hypotheses | #1 |
| v600e mutations dmmr | #1 |
| santner | #1 |
| prognostic impact ploidy | #1 |
| noninferiority adjuvant therapy | #1 |
| mcmo bar | #1 |
| dfs outcomes trials | #1 |
| fuleucovorin | #1 |
| irox ttg | #1 |
| anatomic tumor site | #1 |
| 5year dfs outcomes | #1 |
| bmi mmr status | #1 |
| predefined subgroup | #1 |
| “old” chemotherapy | #1 |
| kras braf asians | #1 |
| initial stage iii | #1 |
| design marker | #1 |
| recist recist version | #1 |
| proposed trial patients | #1 |
| patients isolated sites | #1 |
| quasar2 study | #1 |
| oxaliplatin treatment survival | #1 |
| docetaxel 40 100 | #1 |
| puma dfs | #1 |
| bor response | #1 |
| achievements ncctg | #1 |
| analysis diseasefree survival | #1 |
| concerns recist | #1 |
| foxp3 favorable influence | #1 |
| mcrc reporting | #1 |
| postulated thresholds median | #1 |
| 5 cases outcomes | #1 |
| variance biopsy specific | #1 |
| adverse events response | #1 |
| poms qol | #1 |
| hbd phase | #1 |
| tumor recurrence years | #1 |
| response tritr | #1 |
| treatment benefits sex | #1 |
| cmab folfiri | #1 |
| Sign-in to see all concepts, it's free! | |
Prominent publications by DANIEL J SARGENT
Molecular Markers Identify Subtypes of Stage III Colon Cancer Associated With Patient Outcomes
[ PUBLICATION ]
BACKGROUND & AIMS: Categorization of colon cancers into distinct subtypes using a combination of pathway-based biomarkers could provide insight into stage-independent variability in outcomes.
METHODS: We used a polymerase chain reaction-based assay to detect mutations in BRAF (V600E) and in KRAS in 2720 stage III cancer samples, collected prospectively from patients participating in an adjuvant chemotherapy trial (NCCTG N0147). Tumors deficient or proficient in DNA mismatch repair (MMR) ...
| Known for Patients Tumors | Mutations Braf | Stage Iii | Molecular Markers | Hazard Ratio |
BACKGROUND: Since 2004, a regimen of 6 months of treatment with oxaliplatin plus a fluoropyrimidine has been standard adjuvant therapy in patients with stage III colon cancer. However, since oxaliplatin is associated with cumulative neurotoxicity, a shorter duration of therapy could spare toxic effects and health expenditures.
METHODS: We performed a prospective, preplanned, pooled analysis of six randomized, phase 3 trials that were conducted concurrently to evaluate the noninferiority ...
| Known for 3 Months | Hazard Ratio | Adjuvant Chemotherapy | Oxaliplatin Capox | Iii Colon |
Importance: The association of biomarkers with patient survival after recurrence (SAR) of cancer is poorly understood but may guide management and treatment.
Objective: To determine the association of DNA mismatch repair (MMR) status and somatic mutation in the B-Raf proto-oncogene (c.1799T>A [V600E]; BRAFV600E) or exon 2 of the KRAS proto-oncogene (KRAS) in the primary tumor with SAR in patients with stage III colon carcinomas treated with adjuvant chemotherapy.
Design, Setting, and ...
| Known for Colon Cancer | Recurrence Sar | Patients Tumors | Mismatch Repair | Stage Iii |
BACKGROUND: Tumour mutational status is an important determinant of the response of metastatic colorectal cancer to targeted treatments. However, the genotype of the tissue obtained at the time of diagnosis might not accurately represent tumour genotype after multiple lines of treatment. This retrospective exploratory analysis investigated the clinical activity of regorafenib in biomarker subgroups of the CORRECT study population defined by tumour mutational status or plasma protein ...
| Known for Circulating Dna | Protein Biomarkers | Correct Trial | Kras Mutations | Progressionfree Survival |
PURPOSE: We examined the prognostic impact of specific KRAS mutations in patients with stage III colon adenocarcinoma receiving adjuvant FOLFOX alone or combined with cetuximab in a phase III trial (N0147). Analysis was restricted to BRAF-wild-type tumors, because BRAF mutation was associated with poor prognosis, and BRAF and KRAS mutations are mutually exclusive.
EXPERIMENTAL DESIGN: The seven most common KRAS mutations in codon 12 and codon 13 were examined in 2,478 BRAF-wild-type ...
| Known for Kras Codon | Adjuvant Chemotherapy | Stage Iii | 13 Mutations | Colon Cancer |
Background: The prognostic value of BRAF and KRAS mutations within microsatellite-unstable (MSI) and microsatellite-stable (MSS) subgroups of resected colon carcinoma patients remains controversial. We examined this question in prospectively collected biospecimens from stage III colon cancer with separate analysis of MSI and MSS tumors from patients receiving adjuvant FOLFOX +/- cetuximab in two adjuvant therapy trials.
Methods: Three groups were defined: BRAF Mutant, KRAS Mutant, and ...
| Known for Kras Mutations | Stage Iii | Mss Msi | Patients Braf | Adjuvant Folfox |
DNA Mismatch Repair Status and Colon Cancer Recurrence and Survival in Clinical Trials of 5-Fluorouracil-Based Adjuvant Therapy
[ PUBLICATION ]
BACKGROUND: Approximately 15% of colorectal cancers develop because of defective function of the DNA mismatch repair (MMR) system. We determined the association of MMR status with colon cancer recurrence and examined the impact of 5-fluorouracil (FU)-based adjuvant therapy on recurrence variables.
METHODS: We included stage II and III colon carcinoma patients (n = 2141) who were treated in randomized trials of 5-FU-based adjuvant therapy. Tumors were analyzed for microsatellite ...
| Known for Mismatch Repair | Based Adjuvant | Dmmr Tumors | Cancer Recurrence | Mmr Status |
CONTEXT: Leucovorin, fluorouracil, and oxaliplatin (FOLFOX) is the standard adjuvant therapy for resected stage III colon cancer. Adding cetuximab to FOLFOX benefits patients with metastatic wild-type KRAS but not mutated KRAS colon cancer.
OBJECTIVE: To assess the potential benefit of cetuximab added to the modified sixth version of the FOLFOX regimen (mFOLFOX6) in patients with resected stage III wild-type KRAS colon cancer.
DESIGN, SETTING, AND PARTICIPANTS: A randomized trial of 2686 ...
| Known for Stage Iii | Colon Cancer | Monoclonal Antibodies | Fluorouracil Leucovorin | Wildtype Kras |
Isolated Loss of PMS2 Expression in Colorectal Cancers: Frequency, Patient Age, and Familial Aggregation
[ PUBLICATION ]
PURPOSE: Most colorectal cancers that have high levels of microsatellite instability (MSI-H) show loss of immunohistochemical expression of proteins that participate in the DNA mismatch repair process, most often involving MLH1 and MSH2. Less commonly, a third DNA mismatch repair protein, MSH6, may also be lost as the primary event. Rarely, tumors with MSI-H show normal expression of these three proteins. The genetic deficiency leading to the MSI-H phenotype in such cases is unknown. ...
| Known for Colorectal Cancers | Expression Pms2 | Isolated Loss | Msh2 Msh6 | Repair Proteins |
BACKGROUND: Patients with peritoneal metastatic colorectal cancer have reduced overall survival compared with patients with metastatic colorectal cancer without peritoneal involvement. Here we further investigated the effect of the number and location of metastases in patients receiving first-line systemic chemotherapy.
METHODS: We analysed individual patient data for previously untreated patients enrolled in 14 phase 3 randomised trials done between 1997 and 2008. Trials were included ...
| Known for Metastatic Colorectal | Patients Peritoneal | Systemic Therapy | Metastasis Sites | Individual Patient |
Use of intraoperative electron beam radiotherapy in the management of retroperitoneal soft tissue sarcomas
[ PUBLICATION ]
PURPOSE: To evaluate the disease control, survival results, and tolerance of intraoperative electron beam radiotherapy (IOERT) as a component of treatment for retroperitoneal soft tissue sarcomas.
METHODS AND MATERIALS: Between March 1981 and September 1995, 87 patients with primary (n = 43) or recurrent (n = 44) retroperitoneal or intrapelvic sarcomas received IOERT as a component of treatment at the Mayo Clinic. The tumors were high grade in 54 patients (62%) and low grade in 33 (38%). ...
| Known for Soft Tissue | Local Control | Beam Radiotherapy | Ioert Component | Intraoperative Electron |
Short-term Quality-of-Life Outcomes Following Laparoscopic-Assisted Colectomy vs Open Colectomy for Colon Cancer: A Randomized Trial
[ PUBLICATION ]
CONTEXT: Laparoscopic-assisted colectomy (LAC) has emerged as the preferred minimally invasive surgical strategy for diseases of the colon. The safety and efficacy of LAC for colon cancer are unknown, and the nature and magnitude of any quality-of-life (QOL) benefit resulting from LAC for colon cancer is also unknown.
OBJECTIVE: To compare short-term QOL outcomes after LAC vs open colectomy for colon cancer.
DESIGN, SETTING, AND PARTICIPANTS: Multicenter, randomized controlled trial ...
| Known for Colon Cancer | Lac Colectomy | Life Outcomes | Term Quality | Hospital Length |
Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer
[ PUBLICATION ]
BACKGROUND: Colon cancers with high-frequency microsatellite instability have clinical and pathological features that distinguish them from microsatellite-stable tumors. We investigated the usefulness of microsatellite-instability status as a predictor of the benefit of adjuvant chemotherapy with fluorouracil in stage II and stage III colon cancer.
METHODS: Tumor specimens were collected from patients with colon cancer who were enrolled in randomized trials of fluorouracil-based adjuvant ...
| Known for Adjuvant Chemotherapy | Colon Cancer | Patients Tumors | Hazard Ratio | Instability Status |
PURPOSE: The association of deficient DNA mismatch repair (dMMR) with prognosis in patients with colon cancer treated with adjuvant fluorouracil, leucovorin, and oxaliplatin (FOLFOX) chemotherapy remains unknown.
PATIENTS AND METHODS: Resected, stage III colon carcinomas from patients (N = 2,686) randomly assigned to FOLFOX ± cetuximab (North Central Cancer Treatment Group N0147 trial) were analyzed for mismatch repair (MMR) protein expression and mutations in BRAF(V600E) (exon 15) and ...
| Known for Mismatch Repair | Prognostic Impact | Colon Cancer | Stage Iii | Adjuvant Chemotherapy |
A phase I study of radiation therapy and twice-weekly gemcitabine and cisplatin in patients with locally advanced pancreatic cancer
[ PUBLICATION ]
PURPOSE: In vitro studies suggest that low-dose gemcitabine sensitizes cells to radiation therapy and that this effect persists for 48 h after drug exposure. Cisplatin is a radiation sensitizer and is also synergistic with gemcitabine in some in vitro tumor systems. Gemcitabine's radiosensitizing properties can theoretically be exploited by twice-weekly administration. This study assessed toxicity in patients with pancreatic cancer treated with radiation therapy, gemcitabine, and ...
| Known for Radiation Therapy | Pancreatic Cancer | Gemcitabine Cisplatin | Patients Dose | Grade 3 |
